



NanoPass Technologies Ltd.

NanoPass Technologies: Improving COVID Vaccines and Their Administration

NanoPass is a pioneer in the development and commercialization of skin-delivery solutions for vaccines and aesthetics. Its flagship product, the MicronJet®600, has been shown to reduce the dose of any vaccine (including certain COVID vaccines and most flu vaccines) by x5-10 fold. MicronJet®600 is FDA 510k cleared, CE-marked and has regulatory approvals in China, Brazil, Korea and more. It has been commercialized in many of these markets for delivery of vaccines, allergy testing and aesthetics. The technology is supported by the world's largest clinical database of intradermal vaccination with well over 60 clinical studies and dozens of peer-reviewed publications and is approved for any substance approved for this delivery route.

The Company operates in two discrete markets, vaccines and aesthetics, under specifically-tailored business models: in the aesthetic market, distributorship and private label agreements with major brand owners of injectables (e.g., Fillmed Laboratoires). In the vaccine market, clinical collaborations aimed to improve COVID vaccines developers in anticipation of future license agreements.

NanoPass is also developing next generation products for both the aesthetic and vaccine markets with some of the largest (Top 3) companies in these respective fields.

NanoPass has partnered with a pioneering American R&D company, to develop the world's first self-administration COVID vaccine patch. This first of a kind product will enable simple, reliable and painless self-administration of vaccines directly into the skin. The device will eliminate the use of syringes, needles and vials, and more importantly, any bottlenecks and expenses to injections by healthcare professionals in mass immunizations. This first of a kind device uses our FDA-cleared skin-interface technology, leverages 15 years of clinical development, and will have a superior TPP to IM immunization, including equivalent immunogenicity with lesser side-effects. This approach may allow the world to better battle the COVID pandemic, including its future variants.